Bronchopulmonary Dysplasia
Conditions
Keywords
Neonates, Preterm, Azithromycin, Ureaplasma, Chronic Lung disease, Bronchopulmonary dysplasia
Brief summary
The aim of the TINN2 study is to evaluate the efficacy of azithromycin in prevention of bronchopulmonary dysplasia in preterm neonates.
Detailed description
In contrast to the situation in adults, most medicines used to treat the children of Europe have not been tested and are not authorised for use in children. In particular, 46% medicines prescribed to children in hospital are either unlicensed for their age group or, if licensed, are prescribed off label. Of the children who receive at least one medication in hospital, 67% receive an unlicensed or off-label drug, and in the context of intensive care, this rises to up to 90% of patients. The new Paediatric Regulation entered into force in early 2007 ensure that medicines for use in children are of high quality, ethically evaluated and authorised appropriately. The Paediatric-Use Marketing Authorisation (PUMA) is a new type of marketing authorisation for drugs not covered by a patent, already available on the market for adults. PUMA applies to medicines lacking information and/or appropriate formulation for children of all ages. Thus, the European Medicines Agency (EMA) has published a list of drugs, which azithromycin belongs, as priority medicinal products needing an evaluation in the paediatric population. Bronchopulmonary dysplasia (BPD) is a specific disease of prematurity accompanied by pulmonary inflammation. Multiple factors may contribute to the occurrence of BPD. In infants who are at risk of developing CLD, one frequent finding is colonisation of the preterm lung with the microbe Ureaplasma. Two Meta-Analyses and recent studies have suggested an association between the presence of pulmonary Ureaplasma and the development of BPD. Azithromycin is a macrolide antibiotic active against Ureaplasma spp with anti-inflammatory properties. Thus, it may be effective in reducing the severity of bronchopulmonary diseases in which both infection and inflammation play a role. TINN2 project: the aim of the TINN2 study is to evaluate the efficacy of azithromycin in prevention of bronchopulmonary dysplasia in preterm neonates. TINN2 is a consortium involving European leaders in neonatology, paediatric pharmacology, methodology and several SMEs that will establish links with ethical bodies and regulatory authorities.
Interventions
DRUGAzithromycin
Azithromycin IV 10mg/kg daily for 10 days
DRUGPlacebo
Azithromycin placebo (5% Dextrose) daily for 10 days
Sponsors
University of Liverpool
Cardiff University
University of Nottingham
Erasmus Medical Center
Heinrich-Heine-Universität Düsseldorf (UDUS)
Assistance Publique - Hôpitaux de Paris
Mario Negri Institute (IRFMN)
Advanced Biological Laboratories ABL (ABL SA)
Simcyp Limited (SimCyp)
Only For Children Pharmaceuticals
University of Ulm
Karolinska Institutet
Centre Hospitalier Chrétien (CHC)
Semmelweis University
Institut National de la Santé Et de la Recherche Médicale, France
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
23 Weeks to 28 Weeks
Healthy volunteers
No
Inclusion criteria
1. Pre-term, 28w + 6d gestational age (i.e. 28 weeks and 6 days, including infants born as one of a multiple birth) 2. Requirement for respiratory support within 12hrs of birth (intubated, or by noninvasive mechanical ventilation including continuous positive airway pressure) 3. Presence of an indwelling intravenous line for drug administration 4. Inborn, or born at site within the recruiting centre's neonatal network where follow up will be possible
Exclusion criteria
1. In the opinion of the PI, babies unlikely to survive until 48 hours after birth 2. Exposure to another macrolide antibiotic 3. Presence of major surgical or congenital abnormalities (not including patent ductus arteriosus or patent foramen ovale) 4. Infants born as part of a multiple pregnancy of three or more (i.e. triplets or more) 5. Contraindication of azithromycin as specified in the summary of characteristics of the product. 6. Participation in other clinical trials involving Investigational Medicinal Products (IMPs)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of surviving infants without CLD (Chronic Lung Disease) in the azithromycin treatment group when compared to placebo at 36 weeks post-menstrual age. | 36 weeks post-menstrual age |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Severity of CLD (Chronic Lung Disease) according to NIH definition | 36 weeks PMA | — |
| Microbiology assessment | Baseline and days 5, 10, 21 | Microbiology assessment at baseline and days 5, 10, 21: Pulmonary colonisation by Ureaplasma spp. and Mycoplasma spp. (respiratory culture of endotracheal/nasopharyngeal aspirates and nasogastric aspirates (nasogastric only for Ureaplasma spp. at baseline) and species-specific quantitative PCR) |
| Inflammation Markers | Baseline and days 5, 10, 21 | Subroup of patients: Inflammatory markers at baseline and days 5, 10, 21 in plasma and bronchoalveolar lavage Identification of the following: IL-1, IL-6, IL-8, TNF-a, MCP-1, PMN/Am/TCC, C5a. |
| Duration of positive pressure respiratory support (i.e. conventional mechanical ventilation, nasal ventilation, continuous positive airway pressure, CPAP) and supplemental oxygen | up to 36 weeks PMA | — |
| Emergence of resistance to azithromycin in Ureaplasma spp. isolated from endotracheal or nasopharyngeal samples at baseline, days 5, 10 and 21 | Baseline, days 5, 10 and 21 | On each positive PCR a culture will be performed. Then, an antibiotic susceptibility testing upon positive cultures |
| Resistance to azithromycin among microbes isolated from stool or rectal swab obtained at baseline and day 21 | Baseline and day 21 | Antibiotic susceptibility testing on any identified microbes |
| Plasma concentrations | days 1, 3, 6 as required | Each patients to be allocated two sample timepoints from the following schedule: Sample1: 1 sample within 5 min after the end of dose administration (day 1) Or 1 sample at 6 hours after start of infusion (day 1) Or 1 sample at 12 hours after start of infusion (day 1) Sample 2: 1 sample at 48 hours - just prior to the third administration (day 3) Or 1 sample at 144 hours- just prior to the sixth administration (day 6) |
| Mortality rate (at 28 days, 36 weeks PMA, 2 years) | 28 days, 36 weeks PMA, 2 years | — |
| Development of complications of prematurity | 24 months | Development of complications of prematurity: Nosocomial infection (sepsis, meningitis, pneumonia); intraventricular haemorrhage; necrotising enterocolitis; retinopathy of prematurity; patent ductus arteriosus; pulmonary hemorrhage, pneumothorax and pulmonary interstitial emphysema during hospital stay |
| Number of Adverse Events | 24 months | — |
| Number of participants with dysrhythmic episodes and QTc interval | 24 months | — |
| C-Reactive Protein | 24 months | — |
| Neurodevelopmental assessment: Assessment of neurodevelopment using the 3rd edition of the Bayley Scales of Infant Development at the corrected age of 24 months | 24 months | Long-term follow up at the corrected age of 24 months |
| Respiratory function assessment: Assessment of respiratory symptoms using a validated International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire | 24 months | Long-term follow up at the corrected age of 24 months |
| Exposure to antibiotics other than azithromycin during the hospital stay | up to 36weeks PMA | — |
Countries
Belgium, France, Germany, Hungary, Italy, Luxembourg, Netherlands, Sweden, United Kingdom
Outcome results
None listed